-
公开(公告)号：US12234298B2
公开(公告)日：2025-02-25
申请号：US17238787
申请日：2021-04-23
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Toni Weinschenk , Oliver Schoor , Claudia Trautwein , Norbert Hilf , Steffen Walter , Harpreet Singh
IPC: A61K38/00 , A61K35/17 , A61K39/00 , A61M5/00 , C07K7/06 , C07K7/08 , C07K14/74 , C12N5/0783 , C12N5/0784 , G01N33/574 , C07K7/00
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US11890333B2
公开(公告)日：2024-02-06
申请号：US17390583
申请日：2021-07-30
Applicant: Immatics Biotechnologies GmbH
Inventor： Sabrina Kuttruff-Coqui , Toni Weinschenk , Jens Fritsche , Steffen Walter , Norbert Hilf , Oliver Schoor , Colette Song , Harpreet Singh
IPC: C07K14/47 , C07K14/725 , C07K14/74 , C07K16/28 , C07K16/30 , A61P35/02 , A61P35/00 , A61K35/17 , A61K39/00 , C12N5/0783 , C07K14/705 , C07K7/06 , C07K7/08 , C12Q1/6886
CPC classification number: A61K39/0011 , A61K35/17 , C07K7/06 , C07K7/08 , C07K14/4748 , C07K14/705 , C07K14/70539 , C07K16/2833 , C12Q1/6886 , A61K2039/5158 , A61K2039/572 , A61K2039/80 , C07K2319/33 , C12Q2600/136 , C12Q2600/158 , C12Q2600/16
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US11814446B2
公开(公告)日：2023-11-14
申请号：US17238932
申请日：2021-04-23
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Toni Weinschenk , Steffen Walter , Jens Fritsche , Colette Song , Harpreet Singh
IPC: C07K7/06 , C07K7/08 , C12N5/0783 , C12N9/64 , A61K38/17 , A61K39/00 , A61K45/06 , C07K14/725
CPC classification number: C07K7/08 , A61K38/1709 , A61K39/0011 , A61K45/06 , C07K7/06 , C07K14/7051 , C12N5/0638 , C12N9/6491 , C12Y304/24065 , A61K2039/5158 , A61K2039/572 , C12N2502/11
Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
-
公开(公告)号：US11648276B2
公开(公告)日：2023-05-16
申请号：US16891841
申请日：2020-06-03
Applicant: Immatics Biotechnologies GmbH
Inventor： Toni Weinschenk , Oliver Schoor , Claudia Trautwein , Norbert Hilf , Steffen Walter , Harpreet Singh
IPC: C07K7/06 , C07K14/47 , C07K14/495 , C07K14/725 , A61K35/17 , C07K7/08 , A61K39/00 , C07K16/40 , C07K19/00 , C12N9/02 , C12N9/10 , C12N5/0783 , A61K38/00
CPC classification number: A61K35/17 , A61K39/0011 , C07K7/06 , C07K7/08 , C07K14/47 , C07K14/4748 , C07K14/495 , C07K14/7051 , C07K16/40 , C07K19/00 , C12N5/0638 , C12N9/0036 , C12N9/13 , A61K38/00 , A61K2039/5158 , A61K2039/572 , C07K2317/34 , C07K2319/00 , C12N2502/1157 , C12Y208/02011
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US11273200B2
公开(公告)日：2022-03-15
申请号：US17484703
申请日：2021-09-24
Applicant: Immatics Biotechnologies GmbH
Inventor： Jens Fritsche , Toni Weinschenk , Steffen Walter , Peter Lewandrowski , Harpreet Singh
Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
-
Patent Agency Ranking
公开(公告)号：US11161879B2
公开(公告)日：2021-11-02
申请号：US16599211
申请日：2019-10-11
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Toni Weinschenk , Steffen Walter , Jens Fritsche , Colette Song , Harpreet Singh
Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
-
公开(公告)号：US11161877B2
公开(公告)日：2021-11-02
申请号：US16599198
申请日：2019-10-11
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Toni Weinschenk , Steffen Walter , Jens Fritsche , Colette Song , Harpreet Singh
Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
-
公开(公告)号：US11077171B2
公开(公告)日：2021-08-03
申请号：US17161253
申请日：2021-01-28
Applicant: Immatics Biotechnologies GmbH
Inventor： Jens Fritsche , Toni Weinschenk , Steffen Walter , Peter Lewandrowski , Harpreet Singh
Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
-
公开(公告)号：US10933118B2
公开(公告)日：2021-03-02
申请号：US16894212
申请日：2020-06-05
Applicant: Immatics Biotechnologies GmbH
Inventor： Jens Fritsche , Toni Weinschenk , Steffen Walter , Peter Lewandrowski , Harpreet Singh
Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
-
公开(公告)号：US10905741B2
公开(公告)日：2021-02-02
申请号：US16714098
申请日：2019-12-13
Applicant: Immatics Biotechnologies GmbH
Inventor： Jens Fritsche , Toni Weinschenk , Steffen Walter , Peter Lewandrowski , Harpreet Singh
Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
-
-
-
-
-
-
-
-
-
Search Results
76
records
(took 0.025 seconds)
